Compare DXLG & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DXLG | LGVN |
|---|---|---|
| Founded | 1976 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4M | 34.0M |
| IPO Year | 1994 | 2021 |
| Metric | DXLG | LGVN |
|---|---|---|
| Price | $0.73 | $0.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.50 | ★ $3.00 |
| AVG Volume (30 Days) | 93.1K | ★ 367.9K |
| Earning Date | 05-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $435,017,000.00 | $709,000.00 |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $4.09 | $10.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.44 | $0.48 |
| 52 Week High | $1.69 | $1.80 |
| Indicator | DXLG | LGVN |
|---|---|---|
| Relative Strength Index (RSI) | 61.31 | 47.89 |
| Support Level | $0.48 | $0.74 |
| Resistance Level | $0.82 | $0.86 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 58.35 | 62.76 |
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store and Direct business. The company have two principal operating segments: company's stores and direct business.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.